United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr), docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag), ferrous gluconate (unii: u1b11i423z) (ferrous cation - unii:gw89581owr), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - ascorbic acid 138 mg - bioferr™ 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. these include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence, and dietary needs. hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

mission pharmacal company - iron (unii: e1uol152h7) (iron - unii:e1uol152h7), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag) - ferralet ® 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. these include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs. hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

al multaqa drugs and pharmaceutical spain - 90's[6x15's blister] - capsule - 1000 mg - nutrition , blood-tonics

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

90's[6x15's blister] -

United Arab Emirates - English - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

al ittihad drug store italy - 90’s [6x15’s blister] - capsule - combination - gastrointestinal system-n/a

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - docusate sodium 50 mg - hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

asclemed usa, inc. - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4), liothyronine (unii: 06lu7c9h1v) (liothyronine - unii:06lu7c9h1v) - indications and usage: np thyroid® tablets (thyroid tablets, usp) are indicated: 1. as replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. this category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see warnings). 2. as pituitary tsh suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (hashimoto’s), multinodular goiter, and in the management of thyroid cancer. contraindications: thyroid hormone preparations are generally

United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - levothyroxine (unii: q51bo43mg4) (levothyroxine - unii:q51bo43mg4) - levothyroxine 57 ug

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - omega-3-acid ethyl esters 90, quantity: 1000 mg - capsule, soft - excipient ingredients: purified water; gelatin; glycerol; d-alpha-tocopherol - hypertriglyceridaemia: endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response. treatment is indicated for the following types of dyslipidaemia (fredrickson classification) only: -type iv & v as monotherapy and with close monitoring of ldl-c levels. - type iib as add-on therapy to statins, when control of triglycerides with statins has been shown to be insufficient. patients with higher baseline levels of triglycerides are more likely to exhibit a better response to omacor. omacor is not indicated in exogenous hypertriglyceridaemia (type 1 hyperchylomicronaemia). there are insufficient data to support the use in patients with secondary endogenous hypertriglyceridaemia including patients with diabetes mellitus.

United States - English - NLM (National Library of Medicine)

it3 medical llc - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with iv or im dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection, and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administration , and adverse reactions ). patients should be switched to alternative analgesics a